.AstraZeneca has shared a very early look at the performance of its own internal antibody-drug conju...
.After announcing a period 3 launch based upon good midstage results, iTeos as well as GSK are final...
.The FDA should be actually even more open and collective to unleash a rise in commendations of rare...
.It's an unusually active Friday for biotech IPOs, with Zenas BioPharma, MBX and Bicara Therapies al...
.Atea Pharmaceuticals' antiviral has failed another COVID-19 test, yet the biotech still holds out h...
.Neurocrine Biosciences' schizophrenia plan pivot has fallen short. The biotech was incapable to rep...
.Sanofi has brought in an overdue access to the radioligand party, paying for one hundred thousand e...
.After F2G's initial attempt to acquire a brand-new lesson of antifungal to market was derailed by t...
.Moderna has sworn to reduce R&D spending by $1.1 billion through 2027. The decision to retract t...
.Simply 4 months after Sanofi bet $80 thousand in beforehand money on Pivot Therapies' losmapimod, t...